Vasopine 5

Amlodipine besylate 5mg


Congestive heart failure (CHF)
Persistent progressive dermatologic reactions
Symptomatic hypotension with or without syncope possible, particularly with severe aortic stenosis; because of gradual onset of action, acute hypotension unlikely
Worsening of angina and acute myocardial infarction (MI) can develop after dose is started or increased, particularly with severe obstructive CAD
Peripheral edema may develop within 2-3 weeks of starting therapy
Use with caution in patients with hypertrophic cardiomyopathy; reduction in afterload may worsen symptoms associated with this condition
May reduce coronary perfusion and result in ischemia in patients with severe aortic stenosis; use caution
Extensively metabolized by liver; titrate dose slowly with severe hepatic impairment
Initiate at lower dose in the elderly
Titrate dose every 7-14 days on a given dose; peak antihypertensive effect is delayed
Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction; monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment
Amlodipine may increase systemic exposure of cyclosporine or tacrolimus when co-administered; frequent monitoring of trough blood levels of cyclosporine and tacrolimus recommended; adjust dose when appropriate

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Vasopine 5 only for the indication prescribed.